News

HDA UK Media and Political Bulletin – 6 May 2021

Media Summary

Pharma industry fears Biden’s patent move sets dangerous precedent
Financial Times, Nikou Asgari, Donato Paolo Mancini and Hannah Kuchler, 6 May 2021

The Financial Times reports that the Biden Administration’s announcement to support a temporary waiver of Covid-19 patents has been denounced by the pharmaceutical sector.

Pharmaceutical groups argue that the move would do little to boost Covid-19 vaccine production as it intends. Additionally, they argue that it will discourage US innovation and damage jobs in the US biotech sector. Industry leaders suggested that it would have a limited impact on boosting global production due to the shortage of manufacturing facilities and skilled employees.

Biden’s Trade Adviser, Katherine Tai said that the US Government supported waiving patents for Covid-19 vaccines to help boost global production of jabs, even though the US still “believes strongly” in intellectual property protections.

More than 60 countries have supported the waiver proposal because they believe that vaccine production must increase to contain the virus. The proposal was put forward at the World Trade Organisation in October.

Jeremy Levin, Chair of Biotech Trade Association Bio said: “The Administration’s steps here are very unnecessary and damaging.”

The mRNA technology used in BioNTech/Pfizer and Moderna’s vaccines is being trialled to treat other illnesses such as cancer and heart disease, and pharma lobbyists have claimed that suspending their patents would allow other countries to further develop US research.

The Biden Administration’s move has not yet been supported by the EU and UK.

Parliamentary Coverage

There was no parliamentary coverage today.

 Full Coverage

Pharma industry fears Biden’s patent move sets dangerous precedent
Financial Times, Nikou Asgari, Donato Paolo Mancini and Hannah Kuchler, 6 May 2021

This article is subject to copyright terms and conditions. Please access the full article here.

HDA UK Media and Political Bulletin – 6 May 2021

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?